Phillip A. Sharp is Director at ALNYLAM PHARMACEUTICALS, INC. (ALNY). They have made 5 open-market trades across 1 company since 2019, most recently 2025-01-23.
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ALNY | SELL · 10b5-1 | 2025-01-23 | 2025-01-24 | $275.00 | $3.1M | -0.3% | -10.1% | -12.4% |
| ALNY | SELL · 10b5-1 | 2024-02-29 | 2024-03-01 | $151.52 | $7.0M | -3.1% | +0.1% | -2.0% |
| ALNY | SELL | 2022-08-15 | 2022-08-17 | $230.62 | $12.8M | -6.7% | -4.9% | -4.3% |
| ALNY | SELL | 2022-02-09 | 2022-02-11 | $150.00 | $4.5M | +1.4% | +0.7% | -19.5% |
| ALNY | SELL | 2020-11-25 | 2020-11-30 | $124.89 | $7.5M | -3.6% | +0.2% | +13.7% |
| ALNY | SELL | 2020-02-12 | 2020-02-13 | $130.00 | $3.9M | -9.2% | -24.4% | +7.2% |
| ALNY | SELL | 2019-11-18 | 2019-11-20 | $91.71 | $2.8M | +14.4% | +8.3% | +20.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.